Prescient Therapeutics (PTX) has slipped on the ASX today despite announcing some key developments for its CAR-T cancer therapy programs. The oncology company said today…

The terrible news this week that Tmunity Therapeutics, a clinical stage biotherapeutics company, has halted the development of its lead CAR-T therapy following the deaths…

Australia’s medical community has welcomed a new ‘patent box’ tax regime designed to encourage further investment into local medical and biotech research and development. Under…

The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were…

Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising…

Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with world-renowned Peter MacCallum Cancer Centre to advance its next-generation CAR-T…

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs. CAR-T is a type…

Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its ties in research and development with the world-renowned Peter MacCallum…

Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre to advance work on its revolutionary OmniCAR platform. Under the…

Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid…